Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2014

Open Access 01.12.2014 | Case report

Parotid gland metastasis of lung cancer: a case report

verfasst von: Shuang Shi, Qi-Gen Fang, Fa-Yu Liu, Chang-Fu Sun

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Parotid gland metastasis in lung cancer is extremely rare, very few cases have been reported.

Case presentation

We report on the case of a 61-year-old Chinese male patient who presented with parotid swelling metastasizing from advanced lung cancer. We therefore performed an operation of partial parotidectomy with preservation of the facial nerve and advised the patient receive chemotherapy, however, the patient died four months later.

Conclusion

Although it is extremely rare, a potential metastasis of lung cancer should not be ignored in the diagnosis of parotid tumor. Preoperative routine examination, such as a chest X-ray and lung computational tomography scan, may play an important role in differential diagnosis. The management of the metastatic tumor to the parotid gland was controversial however, despite combined treatment modalities, long-term survival was not attained.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-12-119) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Q-GF and SS contributed to the conception, design, and acquisition of information and write this paper; F-YL and C-FS helped to draft the manuscript and revise the paper. All authors read and approved the final manuscript.
Abkürzungen
CT
computation tomography
TTF
thyroid transcription factor
Syn
Synaptophysin
EMA
epithelial membrane antigen
Ck
cytokeratin.

Background

Lung cancer is a common tumor worldwide and frequently causes cancer-related deaths. It has a propensity to metastasize to any organ. To the best of our knowledge, the site of parotid gland in this case is very unusual and only a few articles have reported [15]. We describe a case of small-cell carcinoma of the lung which spread to the parotid gland.

Case presentation

A 61-year-old Chinese male presented with a progressive painful swelling in the right parotid gland for one month prior to attending our hospital. The patient had a history of heavy smoking, but did not complain of hemoptysis or other symptoms related to lung cancer. A clinical examination showed the size of the mass to be approximately 1 × 1 cm, with a good activity and a moderate texture. An ultrasound showed there to be a hypoechoic nodule with a size of 1.3× 1.3 × 0.9 cm. Therefore our initial diagnosis was that of a primary parotid tumor and we recommended surgical treatment. However, in preoperative routine examinations, a chest X-ray (Figure 1) showed there to be a high density shadow in the right hilar. At this stage we highly suspected that the mass was metastases and required further examination. A lung computational tomography (CT) scan (Figure 2) revealed a shadow in the right upper lobe, with a size of approximately 5.4 × 6.3 cm. The CT value was 40HU, and the enhanced CT value was 60HU, with multiple lymph nodes in the mediastinum appearing enlarged. After consulting with the patient, we performed an operation constituting of a partial parotidectomy and facial nerve dissection. Postoperative pathology reported a small-cell lung cancer metastases to parotid (Figure 3). Immunohistochemistry showed TTF(thyroid transcription factor)-1(+), Syn (Synaptophysin) (+), actin (-), S-100(-), P63 (-), EMA (epithelial membrane antigen) (-), ck(cytokeratin)20 (-). Therefore, we recommended that the patient receive postoperative radiation and chemotherapy.

Discussion

Small-cell lung cancer comprises approximately 15% of bronchogenic carcinomas. It has a high malignancy potential and is usually associated with various paraneoplastic syndromes. At the time of diagnosis the disease is systemically disseminated in many cases, however, the diagnosis sometimes is made from a metastatic focus. The common site of distant spread is the mediastinal and supraclavicular lymph nodes, liver, bone, adrenals, and brain [5, 6]. However, distant metastasis to the parotid gland is a very rare clinical event, to the best of our knowledge. The possible reasons for this may be the anatomical location of the parotid gland and that parenchymal metastasis occurred via hematogenous rather than by lymphatic spread.
As far as we are aware, it is a known fact that most of the metastasis to the submandibular gland are from a distant source, with much fewer being from the head and neck area, which is exactly the opposite when compared to the parotid gland. We hypothesize that the possible reasons for this situation are the difference in the anatomic relationships, number of the lymph nodes, and their drainage between the parotid gland and submandibular gland.
The treatment of metastatic parotid tumor is a matter of debate. Raut et al.[7] presented that, for most tumors restricted to the parotid, a total parotidectomy whilst protecting the facial nerve, followed by radiation therapy, should be the protocol. Nuyens et al.[8] found that the predominant amount of metastatic diseases to the parotid gland were squamous cell carcinomas and malignant melanomas, and concluded that a total or partial parotidectomy with consideration for neck dissection, followed by post-operation radiation, should be included in the treatment. Bumpous et al.[9] reviewed related cases and concluded that, when a positive lymph node was detected in the parotid, a combination of surgical management with postoperative irradiation could increase locoregional control. However, Jecker et al.[10] reported that radical parotid surgery had little effect on improving the life expectancy and concluded that all the current therapeutic procedures were ineffective. In our view, for parotid gland metastases from head and neck cancer origin, a total or partial parotidectomy with a neck dissection is acceptable because of the tendency of the disease to spread via the lymphatic system. For parotid gland metastases originating from a distant organ such as the lung, a neck dissection may be unnecessary because the metastasis is more likely to be caused by hematogenous. In this case, we performed an operation consisting of a partial parotidectomy with preservation of facial nerve, and advised that the patient receive chemotherapy based on the fact that small-cell lung cancer is sensitive to chemotherapy. The patient died four months later, the situation highlighted the fact that metastasis to the parotid gland represented an advanced stage of the disease with a subsequently poor prognosis [5].

Conclusions

Although it is extremely rare, a potential metastasis of lung cancer should not be ignored in the diagnosis of a parotid tumor. Preoperative routine examinations such as a chest X-ray and lung CT, may play an important role in the differential diagnosis. The management of the metastatic tumor to the parotid gland was controversial, however, despite combined treatment modalities long-term survival remained unsuccessful.
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​ ) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Q-GF and SS contributed to the conception, design, and acquisition of information and write this paper; F-YL and C-FS helped to draft the manuscript and revise the paper. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Boeger D, Hocke T, Esser D: Metastasis of a small cell carcinoma to the parotid gland. Laryngorhinootologie. 2005, 84: 117-120. 10.1055/s-2004-826220.CrossRefPubMed Boeger D, Hocke T, Esser D: Metastasis of a small cell carcinoma to the parotid gland. Laryngorhinootologie. 2005, 84: 117-120. 10.1055/s-2004-826220.CrossRefPubMed
2.
Zurück zum Zitat Hisa Y, Tatemoto K: Bilateral parotid gland metastasis as the initial manifestation of a small cell carcinoma of the lung. Am J Otolaryngol. 1998, 19: 140-143. 10.1016/S0196-0709(98)90112-0.CrossRefPubMed Hisa Y, Tatemoto K: Bilateral parotid gland metastasis as the initial manifestation of a small cell carcinoma of the lung. Am J Otolaryngol. 1998, 19: 140-143. 10.1016/S0196-0709(98)90112-0.CrossRefPubMed
3.
Zurück zum Zitat Shalowitz JI, Cassidy C, Anders CB: Parotid metastasis of small cell carcinoma of the lung causing facial nerve paralysis. J Oral Maxillofac Surg. 1988, 46: 404-406. 10.1016/0278-2391(88)90225-X.CrossRefPubMed Shalowitz JI, Cassidy C, Anders CB: Parotid metastasis of small cell carcinoma of the lung causing facial nerve paralysis. J Oral Maxillofac Surg. 1988, 46: 404-406. 10.1016/0278-2391(88)90225-X.CrossRefPubMed
4.
Zurück zum Zitat Borg MF: Parotid gland as an initial site of metastasis. Australas Radiol. 2004, 48: 88-92. 10.1111/j.1440-1673.2004.01253.x.CrossRefPubMed Borg MF: Parotid gland as an initial site of metastasis. Australas Radiol. 2004, 48: 88-92. 10.1111/j.1440-1673.2004.01253.x.CrossRefPubMed
5.
Zurück zum Zitat Ulubas B, Ozcan C, Polat A: Small cell lung cancer diagnosed with metastasis in parotid gland. J Craniofac Surg. 2010, 21: 781-783. 10.1097/SCS.0b013e3181d7f186.CrossRefPubMed Ulubas B, Ozcan C, Polat A: Small cell lung cancer diagnosed with metastasis in parotid gland. J Craniofac Surg. 2010, 21: 781-783. 10.1097/SCS.0b013e3181d7f186.CrossRefPubMed
6.
Zurück zum Zitat Sher T, Dy GK, Adjei AA: Small cell lung cancer. Mayo Clinic Proc. 2008, 83: 355-367. 10.4065/83.3.355.CrossRef Sher T, Dy GK, Adjei AA: Small cell lung cancer. Mayo Clinic Proc. 2008, 83: 355-367. 10.4065/83.3.355.CrossRef
7.
Zurück zum Zitat Raut V, Sinnathuray AR, Primrose WJ: Aggressive treatment of metastasis to the parotid. Ulster Med J. 2004, 73: 85-88.PubMedCentralPubMed Raut V, Sinnathuray AR, Primrose WJ: Aggressive treatment of metastasis to the parotid. Ulster Med J. 2004, 73: 85-88.PubMedCentralPubMed
8.
Zurück zum Zitat Nuyens M, Schüpbach J, Stauffer E, Zbaren P: Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg. 2006, 135: 844-848. 10.1016/j.otohns.2006.05.010.CrossRefPubMed Nuyens M, Schüpbach J, Stauffer E, Zbaren P: Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg. 2006, 135: 844-848. 10.1016/j.otohns.2006.05.010.CrossRefPubMed
9.
Zurück zum Zitat Bumpous J: Metastatic cutaneous squamous cell carcinoma to the parotid and cervical lymph nodes: treatment and outcomes. Curr Opin Otolaryngol Head Neck Surg. 2009, 17: 122-125. 10.1097/MOO.0b013e32832924e0.CrossRefPubMed Bumpous J: Metastatic cutaneous squamous cell carcinoma to the parotid and cervical lymph nodes: treatment and outcomes. Curr Opin Otolaryngol Head Neck Surg. 2009, 17: 122-125. 10.1097/MOO.0b013e32832924e0.CrossRefPubMed
10.
Zurück zum Zitat Jecker P, Hartwein J: Metastasis to the parotid gland: is a radical surgical approach justified. Am J Otolaryngol. 1996, 17: 102-105. 10.1016/S0196-0709(96)90004-6.CrossRefPubMed Jecker P, Hartwein J: Metastasis to the parotid gland: is a radical surgical approach justified. Am J Otolaryngol. 1996, 17: 102-105. 10.1016/S0196-0709(96)90004-6.CrossRefPubMed
Metadaten
Titel
Parotid gland metastasis of lung cancer: a case report
verfasst von
Shuang Shi
Qi-Gen Fang
Fa-Yu Liu
Chang-Fu Sun
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2014
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-119

Weitere Artikel der Ausgabe 1/2014

World Journal of Surgical Oncology 1/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.